Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mitoparaquat (MPQ) is a mitochondria-targeted redox cycler designed to selectively generate superoxide within the mitochondrial matrix. It consists of a paraquat (methyl viologen) moiety conjugated to a lipophilic triphenylphosphonium (TPP) cation, which facilitates its accumulation across the mitochondrial inner membrane driven by the membrane potential. Once inside the mitochondria, it undergoes redox cycling at the flavin site of Complex I (NADH:ubiquinone oxidoreductase), leading to the production of mitochondrial reactive oxygen species (mtROS), specifically superoxide. It is primarily used as a research tool to study the role of mtROS in various pathological conditions, including epilepsy, neurodegeneration, and astrogliosis, by mimicking mitochondrial oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mitoparaquat.